Atlas Arteria Limited (OTCMKTS:MAQAF – Get Free Report) shares were down 10.5% on Tuesday. The stock traded as low as $2.64 and last traded at $2.64. Approximately 360 shares traded hands during mid-day trading, a decline of 70% from the average session volume of 1,203 shares. The stock had previously closed at $2.95.
Analysts Set New Price Targets
MAQAF has been the topic of several research reports. Royal Bank Of Canada downgraded shares of Atlas Arteria to an “underperform” rating and set a $4.75 price target on the stock. in a research note on Thursday, July 2nd. Jefferies Financial Group upgraded Atlas Arteria to a “buy” rating and set a $5.31 target price for the company in a research report on Thursday, August 27th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Atlas Arteria presently has an average rating of “Hold” and a consensus target price of $5.03.
Get Our Latest Research Report on Atlas Arteria
Atlas Arteria Trading Down 10.5%
The company has a fifty day simple moving average of $3.28 and a 200 day simple moving average of $3.35.
About Atlas Arteria
Atlas Arteria Group is an owner and manager of transportation infrastructure assets, with a focus on toll roads and related concessions. The company invests in, develops and operates long-term road infrastructure under public-private partnership and concession arrangements, generating revenue from toll collections and other transportation-related activities.
Atlas Arteria’s portfolio includes interests in the APRR and AREA motorway networks in France, which together form one of the country’s major tolled motorway systems.
Further Reading
- Five stocks we like better than Atlas Arteria
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
Receive News & Ratings for Atlas Arteria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atlas Arteria and related companies with MarketBeat.com's FREE daily email newsletter.
